SCHEMBL4475940

SCHEMBL4475940

COc1cc2nccc(Oc3ccc(CN)cc3)c2cc1OC

nearest known ligand 0.74

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.68
PDGFRA P16234 1/20 0.68
FGFR2 P21802 6/20 0.64
EGFR P00533 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17489327 0.86 PDGFRA (0.68) PDGFRBPDGFRAFGFR2EGFR
SCHEMBL7486400 0.86 FGFR2 (0.84) PDGFRBPDGFRAFGFR2EGFR
SCHEMBL167396 0.85 PDGFRA (0.74) PDGFRBPDGFRAFGFR2EGFR
SCHEMBL29973104 0.84 PDGFRA (0.61) PDGFRBPDGFRAFGFR2
Hydrochloric Acid SCHEMBL23528156 0.83 PDGFRA (0.72) PDGFRBPDGFRAFGFR2EGFR
SCHEMBL12444104 0.83 PDGFRA (0.76) PDGFRBPDGFRAFGFR2EGFR
SCHEMBL2172904 0.82 PDGFRA (0.64) PDGFRBPDGFRAFGFR2
SCHEMBL7484470 0.82 PDGFRA (0.74) PDGFRBPDGFRAFGFR2EGFR
SCHEMBL16083535 0.82 PDGFRA (0.74) PDGFRBPDGFRAFGFR2EGFR
SCHEMBL4470477 0.82 PDGFRA (0.74) PDGFRBPDGFRAFGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors FGFR1, FGFR2, FGFR3 PDGFRB 202/4885PDGFRA 372/4885FGFR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.